Coherus Oncology
CHRS
109 hedge funds and large institutions have $1.05B invested in Coherus Oncology in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
21% more capital invested
Capital invested by funds: $867M → $1.05B (+$182M)
1.05% less ownership
Funds ownership: 94.83% → 93.79% (-1%)
5% less funds holding
Funds holding: 115 → 109 (-6)
14% less call options, than puts
Call options by funds: $4.83M | Put options by funds: $5.65M
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hound Partners
New York
|
+$21.8M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.8M |
| 3 |
BlackRock
New York
|
+$8.57M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.21M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
+$6.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$11M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.83M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.68M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.69M |
CHRS Hedge Fund Activity: Q3 2018 in Review
109 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2018, worth a combined $1.05B — up 21% from $867M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CHRS and 8 opened new positions — a net loss of 6 holders — while 40 trimmed existing stakes and 49 added.
The largest buyer was Hound Partners, adding an estimated $21.8M. The largest seller was Marshall Wace North America, cutting an estimated $11M.
- 109 institutional investors held Coherus Oncology (CHRS) as of Q3 2018, down from 115 in Q2 2018.
- Funds reported $1.05B of Coherus Oncology stock for Q3 2018, up 21% quarter-over-quarter.
- 8 funds opened new Coherus Oncology positions in Q3 2018 and 14 closed out, a net change of -6 holders.
- The largest Coherus Oncology buyer in Q3 2018 was Hound Partners, an estimated $21.8M added.
- The largest Coherus Oncology seller in Q3 2018 was Marshall Wace North America, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2018.